

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
07 April 2022 (07.04.2022)



(10) International Publication Number
WO 2022/072292 A1

(51) International Patent Classification:

A61K 51/00 (2006.01) A61K 51/10 (2006.01)
A61K 51/04 (2006.01) A61P 35/00 (2006.01)
A61K 51/08 (2006.01)

(21) International Application Number:

PCT/US2021/052269

(22) International Filing Date:

28 September 2021 (28.09.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/086,163 01 October 2020 (01.10.2020) US

(71) Applicant: CORNELL UNIVERSITY [US/US]; Center
For Technology Licensing ("CTL") At Cornell University,
395 Pine Tree Road, Suite 310, Ithaca, NY 14850 (US).

(72) Inventor: BANDER, Neil H.; 1330 1st Ave, Apt. 1119,
New York, NY 10021 (US).

(74) Agent: GOLDMAN, Michael L. et al.; Troutman Pepper
Hamilton Sanders, 70 Linden Oaks, Suite 210, Rochester,
NY 14625 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,

(54) Title: METHODS AND COMPOSITIONS FOR INCREASING UPTAKE, INTERNALIZATION, AND/OR RETENTION OF
SMALL MOLECULE LIGANDS




FIG. 1A

(57) Abstract: The present application relates to methods of treating and imaging cancer. The methods involve providing a first agent comprising a first targeting component coupled to a cancer therapeutic component or an imaging component and providing a second agent comprising a second targeting component alone, wherein the second targeting component increases the uptake, internalization, and/or retention of the first targeting component coupled to a cancer therapeutic component or imaging component. The first and second agents are then administered to a subject having cancer to treat cancer. Also disclosed is a combination therapeutic or a combination imaging system, each comprising the first and second agents.

[Continued on next page]



WO 2022/072292 A1

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))